ClinicalTrials.gg
RecruitingNCT07243782Updated Mar 5, 2026

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

An observational study in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and Juvenile Idiopathic Arthritis, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in South Korea. Open to participants aged 6 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
76
Ages
6 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Planned enrollment
8th of 10
76 · median 125
Started
2025
with 6 others
Observational
10 of 21
6 open now
Primary completion
2027-06
later than 5 of 13 live
Registered
15th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2025, is one of 10 observational ones, reaches primary completion later than 5 of the 13 other live ones, and was the 15th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 6 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea

Read the detailed description

This post-marketing study is a multicenter, single-arm, prospective, observational study.

Cosentyx is prescribed within the scope of the approved indications for hidradenitis suppurativa, pediatric plaque psoriasis, enthesitis-related arthritis and juvenile psoriatic arthritis in the juvenile idiopathic arthritis category. The decision to treat patients with the drug will be made within current clinical practice and will be clearly distinguished from the decision to include patients in this investigation. No additional diagnostics or monitoring will be performed for this study beyond what is typically performed in clinical practice.

03

Conditions studied

  • Hidradenitis Suppurativa
  • Pediatric Plaque Psoriasis
  • Juvenile Idiopathic Arthritis
04

Who can participate

Ages eligible
6 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Hidradenitis suppurativa:

  1. Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.
  2. Patients who have agreed to participate in study (written )

Pediatric plaque psoriasis:

  1. Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.
  2. Patients with patient or guardian consent to participate in study (written informed consent)

Juvenile idiopathic arthritis:

  1. Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.
  2. Patients with patient or guardian consent to participate in study (written informed consent)

Exclusion criteria

Exclusion Criteria:

  1. Patients who are according to national prescribing information
  2. Patients participating in other interventional clinical trials
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
76 participants (estimated)
Patient registry
No

Groups and cohorts

  • Secukinumab - HS

    Participants with Hidradenitis Supurativa who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.

    Drug: Secukinumab

  • Secukinumab - Pediatric plaque psoriasis

    Participants with pediatric plaque psoriasis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.

    Drug: Secukinumab

  • Secukinumab - JIA

    Participants with juvenile idiopathic arthritis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.

    Drug: Secukinumab

Interventions

  • This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

    Also known as: Cosentyx

06

What researchers measure

Primary outcomes

  1. Number of participants having Adverse Events (AEs) and Serious Adverse Events (SAEs) within each indication

    All AEs, regardless of severity or causality, will be collected from all participants enrolled in the study.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Proportion of paticipants achieving 50% reduction in hidradenitis suppurativa clinical response (HiSCR50) - HS participants

    The HiSCR is a validated assessment tool developed for patients with hidradenitis suppurativa. It is a dichotomized clinical response assessment that measures the status of three types of lesions: abscesses, inflammatory nodules, and draining fistulas. HiSCR50 is defined as participants who have at least a 50% reduction in abscess and nodule count compared to baseline and no increase in the number of abscesses or draining tunnels.

    Time frame: 12 and 24 weeks

  2. Proportion of participants achieving a severity of 0 or 1 on the hidradenitis supurativa-physician's global assessment (HS-PGA) - HS participants

    The HS-PGA is a global assessment of patients with hidradenitis suppurativa based on four clinical assessments \[number of abscesses, number of draining fistulas, number of inflammatory nodules, and presence/absence of non-inflammatory nodules\] to determine severity on a six-point scale, scores range from 0-5 based on the number of HS lesions ranges from clear to very severe.

    Time frame: 12 and 24 weeks

  3. Proportion of participants with a 55% or greater reduction in international hidradenitis suppurativa severity scoring system (IHS4-55) - HS participants

    The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. HS4-55 is defined as participants who have at least a 55% reduction in IHS4 score compared to baseline.

    Time frame: 12 and 24 weeks

  4. Proportion of participants with a ≥30% reduction in Hidradenitis suppurativa-related skin pain numerical rating scale (NRS) - HS participants

    The HS-related skin pain NRS is a numeric rating scale in which patients rate their pain at the time of the worst skin pain in the past 24 hours. The numeric rating scale is a fine-grained numeric version of a visual analogue scale (VAS) in which respondents select a number (0-10) that best reflects the intensity of their pain, ranging from 0 (no skin pain) to 10 (most severe skin pain)

    Time frame: 12 and 24 weeks

  5. Proportion of participants with an Hidradenitis supurativa flare - HS participants

    An HS flare is a new or substantial worsening of clinical signs or symptoms.

    Time frame: 12 and 24 weeks

  6. Proportion of participants by Hurley stage - HS participants

    The Hurley stage is a grading system for classifying the severity of hidradenitis suppurativa. Stage I is defined as abscess formation (single or multiple), no sinus tracts or cicatrization/scarring, Stage II is defined as recurrent abscesses with sinus tracts and scarring, single or multiple separated lesions, and Stage III is defined as diffuse or almost diffuse involvement, or multiple interconnected sinus tracts and abscesses across the entire area.

    Time frame: 12 and 24 weeks

  7. Change from baseline in Psoriasis Area and Severity Index (PASI) - Pediatric plaque psoriasis participants

    The PASI is a composite index that combines the area of involvement of psoriatic lesions with the severity of the lesions. The PASI calculates the extent of redness/erythema, scaling, and thickness/thickness of psoriatic lesions and assesses their severity with a corresponding score. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a theoretic maximum of 72.0.

    Time frame: 12 and 24 weeks

  8. Proportion of participants achieving an Investigator's Global Assessment (IGA) score of 0 or 1 - Pediatric plaque psoriasis participants

    The IGA mod 2011 score is used to determine the severity psoriasis symptoms. It reflects a subject's overall disease severity for the whole body. The scale includes 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

    Time frame: 12 and 24 weeks

  9. Change from baseline in active joints by Tender Joint Count (TJC) - JIA participants

    A joint is classified as "active" when there is swelling, pain on movement, tenderness/pain on movement, and limitation of motion. It is also possible to classify a joint as "active" if only edema is present. Using digital pressure, joints that feel tender or show pain when moved are considered tender joints, and their counts are totaled to determine the tender joint count (TJC).

    Time frame: 12 and 24 weeks

  10. Change from baseline in active joints by swollen joint count (SJC)- JIA participants

    A joint is classified as "active" when there is swelling, pain on movement, tenderness/pain on movement, and limitation of motion. It is also possible to classify a joint as "active" if only edema is present. Swollen joint count SJC is determined by physical examination of joint counts that are classified as either swollen or not swollen.

    Time frame: 12 and 24 weeks

  11. Change from baseline in clinical juvenile arthritis disease activity score (cJADAS) - JIA participants

    The JADAS is a tool for assessing disease activity in Juvenile idiopathic arthritis that is composed of four items: joint count (number of active joints as assessed by a physician), physician global assessment of disease activity (VAS 0-10), parent/patient global assessment (VAS 0-10), and serum inflammatory markers (erythrocyte sedimentation rate (ESR)), which are scored separately and summed to calculate a score. The clinical JADAS (cJADAS) used in this study excludes serum inflammatory markers and is calculated by summing all the scores (0-10) obtained from each item, and the score is calculated from a minimum of 0 to a maximum of 30.

    Time frame: 12 and 24 weeks

  12. Physician evaluation of participant symptoms

    Treatment effect is evaluated by physician based on clinical judgement and/or laboratory test results and classified in four categories. * Improved: improvement or maintenance of symptoms\*, as determined by the investigator. * Unchanged: No significant change from pre-initiation of the investigational drug is identified, which is not considered a maintenance effect\*. * Worsening: Symptoms are worse than before started taking the investigational drug. * Unevaluable: Unable to evaluate due to lost to follow-up, etc. \* Maintenance effect: When there is a significant risk of worsening of symptoms if the medication is discontinued, or when substitution with an existing medication continues to have an equivalent effect.

    Time frame: 12 and 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative Site
    Seoul, Seoul 06973, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 46 observational studies under Hidradenitis Suppurativa, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 25. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartActual
Dec 22, 2025
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07243782
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Dec 22, 2025
Primary completion
Jun 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion